We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Cross-reactive antibodies after SARS-CoV-2 infection and vaccination.
- Authors
Grobben, Marloes; van der Straten, Karlijn; Brouwer, Philip J. M.; Brinkkemper, Mitch; Maisonnasse, Pauline; Dereuddre-Bosquet, Nathalie; Appelman, Brent; Lavell, A. H. Ayesha; van Vught, Lonneke A.; Burger, Judith A.; Poniman, Meliawati; Oomen, Melissa; Eggink, Dirk; Bijl, Tom P. L.; van Willigen, Hugo D. G.; Wynberg, Elke; Verkaik, Bas J.; Figaroa, Orlane J. A.; de Vries, Peter J.; Boertien, Tessel M.
- Abstract
Current SARS-CoV-2 vaccines are losing efficacy against emerging variants and may not protect against future novel coronavirus outbreaks, emphasizing the need for more broadly protective vaccines. To inform the development of a pan-coronavirus vaccine, we investigated the presence and specificity of cross-reactive antibodies against the spike (S) proteins of human coronaviruses (hCoV) after SARS-CoV-2 infection and vaccination. We found an 11- to 123-fold increase in antibodies binding to SARS-CoV and MERS-CoV as well as a 2- to 4-fold difference in antibodies binding to seasonal hCoVs in COVID-19 convalescent sera compared to pre-pandemic healthy donors, with the S2 subdomain of the S protein being the main target for cross-reactivity. In addition, we detected cross-reactive antibodies to all hCoV S proteins after SARS-CoV- 2 vaccination in macaques and humans, with higher responses for hCoV more closely related to SARS-CoV- 2. These findings support the feasibility of and provide guidance for development of a pan-coronavirus vaccine.
- Subjects
SARS-CoV-2; CONVALESCENT plasma; COVID-19 pandemic; COVID-19; IMMUNOGLOBULINS
- Publication
eLife, 2021, p1
- ISSN
2050-084X
- Publication type
Article
- DOI
10.7554/eLife.70330